Bioton Liabilities 2024

Bioton Aktienanalyse

What does Bioton do?

Bioton SA is a leading Polish biotechnology company specializing in the development of innovative drugs, diagnostics, and medical devices. The company was founded in 1989 and has since achieved remarkable success. Bioton is headquartered in Poland and employs approximately 1000 people worldwide. The company is listed on the Warsaw Stock Exchange and is supported by renowned investors. Business model Bioton operates various business divisions, including research and development, production, sales, as well as marketing and distribution. The company collaborates closely with leading academic institutions and research organizations and invests significant resources in the development of new groundbreaking technologies and products. The company's products and services are distributed and used in over 60 countries worldwide. Divisions Bioton is divided into three main business sectors, including biopharmaceuticals, diagnostics, and medical devices. Biopharmaceuticals Bioton is known for its biopharmaceuticals, particularly insulin and insulin analogs. Insulin is a hormone produced by the body to regulate blood sugar levels. Bioton offers various insulin products, including human insulin, insulin glargine, and insulin aspart. These products are approved for the treatment of diabetes mellitus and are distributed in over 50 countries worldwide. Diagnostics Bioton is also involved in the development and production of diagnostics. The company offers various testing systems for the diagnosis of infectious diseases, allergies, and autoimmune diseases. The product line also includes in vitro diagnostics that are used for medical therapy monitoring and disease detection. Medical devices Bioton also manufactures and distributes medical devices such as insulin pumps and blood glucose meters. These devices are designed for people with diabetes and assist in accurate insulin dosing and blood sugar level monitoring. Products In addition to insulin and insulin analogs, Bioton also produces a wide range of other drugs, including growth hormones, as well as follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These hormones are used for the treatment of infertility. Bioton is also involved in the development of novel technologies such as RNA interference (RNAi) and genomic research. The company invests significantly in innovative research projects aimed at the development of groundbreaking drugs and therapies. In conclusion, Bioton SA is a highly innovative biotechnology company with a wide range of products and a focus on research and development. The company operates in the global market and collaborates closely with renowned institutions and research organizations. Bioton's business model is based on the development of innovative technologies and products aimed at improving the quality of life for people worldwide. Bioton ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Bioton's Liabilities

Bioton's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Bioton's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Bioton's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Bioton's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Bioton’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Bioton stock

What is the level of liabilities of Bioton this year?

Bioton has a debt balance of 215.87 M PLN this year.

What were the liabilities of Bioton compared to the previous year?

The liabilities of Bioton have increased by 5.68% increased compared to the previous year.

What are the consequences of high debt for investors of Bioton?

High liabilities can pose a risk for investors of Bioton, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Bioton?

Low liabilities mean that Bioton has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Bioton affect the company?

An increase in liabilities of Bioton can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Bioton affect the company?

A decrease in the liabilities of Bioton can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Bioton?

Some factors that can influence the liabilities of Bioton include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Bioton so important for investors?

The liabilities of Bioton are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Bioton take to modify the liabilities?

To change its liabilities, Bioton can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Bioton pay?

Over the past 12 months, Bioton paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bioton is expected to pay a dividend of 0 PLN.

What is the dividend yield of Bioton?

The current dividend yield of Bioton is .

When does Bioton pay dividends?

Bioton pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bioton?

Bioton paid dividends every year for the past 0 years.

What is the dividend of Bioton?

For the upcoming 12 months, dividends amounting to 0 PLN are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bioton located?

Bioton is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bioton kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bioton from 9/9/2024 amounting to 0 PLN, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did Bioton pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of Bioton in the year 2023?

In the year 2023, Bioton distributed 0 PLN as dividends.

In which currency does Bioton pay out the dividend?

The dividends of Bioton are distributed in PLN.